6L9.F ViewRay, Inc. at €0.025 on XETRA after hours Jan 2026: high-volume mover
6L9.F stock surged to €0.025 on XETRA after hours on 23 Jan 2026, trading 3,500 shares and showing a one-day move of +2,400.00%. We flag the spike as a high-volume mover driven by low float and thin intraday liquidity, not by a confirmed earnings beat. ViewRay, Inc. (6L9.F) remains a volatile healthcare device name with a long-term 50-day average of €0.32 and 200-day average of €2.72, which frames the risk-reward for traders.
Price and volume snapshot for 6L9.F stock
6L9.F stock closed the aftermarket session at €0.025, up €0.024 from a previous close of €0.001. Volume surged to 3,500 versus an average volume of 279, giving a relative volume of 12.54, a classic sign of short-term momentum and price discovery.
Catalysts and recent news drivers for 6L9.F stock
There is no confirmed company earnings release tied to this move today. ViewRay markets the MRIdian MRI-guided radiation therapy platform, which can drive investor interest when hospital procurement news appears. Check official releases on the company site for filings and press updates: ViewRay investor news and ViewRay homepage.
Fundamental snapshot and valuation for 6L9.F stock
ViewRay reports EPS -€0.55, P/E -0.05, and a market cap near €207,228,256 on XETRA. Key ratios include Price/Sales 2.38, Price/Book 0.06, and current ratio 2.36, which shows short-term liquidity but persistent operating losses. Receivables days at 147.79 and R&D intensity at 31.73% of revenue underline capital needs and long sales cycles in medical devices.
Meyka AI rates 6L9.F with a score out of 100: 57.43 | Grade C+ | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.
Technical outlook and trading signals for 6L9.F stock
Short-term support sits near the intraday low €0.001 and resistance near the session high €0.025. The 50-day average at €0.32 and 200-day average at €2.72 are far above current price, signaling a steep mean-reversion gap for momentum traders. Given the small share price and low float dynamics, limit orders and tight position sizing are prudent to manage slippage.
Risks and opportunities affecting 6L9.F stock
Opportunities: adoption of MRIdian systems in cancer centers could boost multi-year revenue and narrow losses. Risks: long sales cycles, high receivables days, and debt-to-equity 1.05 raise execution risk. The stock’s year high at €4.60 and year low at €0.0005 show extreme volatility and headline sensitivity that investors must price into scenarios.
High-volume trading strategy for 6L9.F stock
As a high-volume mover on XETRA, traders should use small position sizes and predefined stop-loss levels. Consider scaling entries on confirmed follow-through above €0.05 and use profit targets at €0.08 and €0.12, with a downside stop near €0.005 for capital protection. Monitor order book depth tightly during aftermarket sessions.
Final Thoughts
Key takeaways: 6L9.F stock spiked to €0.025 after hours on 23 Jan 2026 on heavy volume, driven primarily by thin liquidity and momentum rather than confirmed corporate news. Fundamentals show negative EPS -€0.55, Price/Book 0.06, and a current ratio of 2.36, which provide some balance between cash buffers and ongoing losses. Meyka AI’s forecast model projects a 12-month median price of €0.12, implying an upside of 380.00% versus the current price of €0.025; forecasts are model-based projections and not guarantees. Given the C+ (57.43) Meyka grade and high volatility, we frame ViewRay as a speculative, event-driven trade for size-limited accounts and a hold for longer-term investors pending clearer adoption signals and improved margins. Use strict risk controls and watch official ViewRay communications for material updates.
FAQs
What caused the 6L9.F stock spike after hours today?
The aftermarket jump to €0.025 was driven by thin liquidity and heavy trading volume, not by a confirmed earnings release. Low float and a rel. volume of 12.54 amplified price moves on XETRA.
How does Meyka AI grade 6L9.F stock and what does it mean?
Meyka AI rates 6L9.F with a score out of 100 at 57.43, Grade C+, suggestion HOLD. The grade blends benchmark, sector, key metrics, and forecast data; it is informational and not investment advice.
What are practical trading levels for 6L9.F stock after this move?
Use tight sizing. Short-term resistance marks are €0.05 and €0.08. A conservative profit target is €0.12 and a downside stop near €0.005 to limit losses in this volatile name.
Does Meyka AI provide a price forecast for 6L9.F stock?
Yes. Meyka AI’s forecast model projects a 12-month median of €0.12, implying 380.00% upside versus €0.025. Forecasts are model-based projections and not guarantees.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
